• 1
    Skinner HA, Holt S, Schuller R, Roy J, Israel Y. Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med 1984; 101: 84751.
  • 2
    Conigrave KM, Saunders JB, Reznik RB, Whitfield JB. Prediction of alcohol-related harm by laboratory test results. Clin Chem 1993; 39: 226670.
  • 3
    Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, Helander A, Tabakoff B. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002; 26: 3329.
  • 4
    Trell E, Kristenson H, Fex G. Alcohol-related problems in middle-aged men with elevated serum gamma-glutamyltransferase: a preventive medical investigation. J Stud Alcohol 1984; 45: 3029.
  • 5
    Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142: 699708.
  • 6
    Brenner H, Rothenbacher D, Arndt V, Schuberth S, Fraisse E, Fliedner TM. Distribution, determinants, and prognostic value of γ-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev Med 1997; 26: 30510.
  • 7
    Arndt V, Brenner H, Rothenbacher D, Zschenderlein B, Fraisse E, Fliedner TM. Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health 1998; 71: 40512.
  • 8
    Karlson BW, Wiklund O, Hallgren P, Sjolin M, Lindqvist J, Herlitz J. Ten-year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia. J Intern Med 2000; 247: 44956.
  • 9
    Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000; 31: 18515.
  • 10
    Bots ML, Salonen JT, Elwood PC et al. γ -Glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Community Health 2002; 56 (Suppl I): i259.
  • 11
    Arnesen E, Huseby NE, Brenn T, Try K. The Tromsø Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 1986; 46: 6370.
  • 12
    Nilssen O, Førde OH, Brenn T. The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990; 132: 31826.
  • 13
    Robinson D, Whitehead TP. Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening. Ann Clin Biochem 1989; 26: 393400.
  • 14
    Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 184450.
  • 15
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91100.
  • 16
    Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9: 1015.
  • 17
    Kornhuber J, Kornhuber HH, Backhaus B, Kornhuber A, Kaiserauer C, Wanner W. The normal values of gamma-glutamyltransferase are falsely defined up to now: on the diagnosis of hypertension, obesity and diabetes with reference to ‘‘normal’’ consumption of alcohol (in German). Versicherungsmedizin 1989; 41: 7881.
  • 18
    Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum γ-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 7327.
  • 19
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 118397.
  • 20
    Japan Society of Clinical Chemistry Recommendation for measuring enzyme activity in human serum (in Japanese with English abstract). Jpn J Clin Chem 1989; 18: 21162.
  • 21
    Nakanishi N, Suzuki K, Tatara K. Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. Diabetes Care 2003; 26: 4854.
  • 22
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 23
    Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol 1989; 2: 6974.
  • 24
    Wenzel DG, Hale TW. Toxicity of free fatty acids for cultured rat heart muscle and endothelioid cells. I. Saturated long-chain fatty acids. Toxicology 1978; 11: 10917.
  • 25
    Kissebah AH. Insulin resistance in visceral obesity. Int J Obes 1991; 15: 10915.
  • 26
    Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 1995; 19: 8415.
  • 27
    Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995; 19: 84650.
  • 28
    Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 1974; 53: 6476.
  • 29
    Memon RA, Feingold KR, Grunfeld C. Cytokines and intermediary metabolism. In: RemickDG, FriedlandJS, eds. Cytokines in health and disease, 2nd edn. Marcel Dekker, New York, 1997; pp. 38199.
  • 30
    Yin M, Wheeler MD, Kono H et al. Essential role of tumor necrosis factor in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 94252.
  • 31
    Sim E. Humoral Factors. IRL Press, Oxford, 1993.
  • 32
    Facchini F, Hollenbeck CB, Chen YN, Chen YD, Reaven GM. Demonstration of a relationship between white blood cell count, insulin resistance, and several risk factors for coronary heart disease in women. J Intern Med 1992; 232: 26772.
  • 33
    Targher G, Seidell JC, Tonoli M, Muggeo M, De Sandre G, Cigolini M. The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. J Intern Med 1996; 239: 43541.
  • 34
    Stolk RP, van Splunder IP, Schouten JS, Witteman JC, Hofman A, Grobbee DE. High blood pressure and the incidence of non-insulin dependent diabetes mellitus: findings in a 11.5 year follow-up study in The Netherlands. Eur J Epidemiol 1993; 9: 1349.
  • 35
    Morales PA, Mitchell BD, Valdez RA, Hazuda HP, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 1993; 42: 15461.
  • 36
    Kissebah AH, Vydelingum N, Murray R et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 25460.
  • 37
    Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72: 115062.
  • 38
    Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989; 73: 11138.
  • 39
    Pouliot MC, Despés JP, Nadeau A et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 82634.